Inactive Instrument

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

US66737P5017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

31/10	Northwest Biotherapeutics, Inc. Enters into Commercial Loan Agreement with Streeterville Capital, LLC for USD 5,505,000	CI
09/10	Northwest Biotherapeutics, Advent Bioservices And The UK National Health Service Blood And Transplant Announce Collaboration To Support DCVax®-L Production	CI

Valuation: Northwest Biotherapeutics, Inc

Market Cap	30Cr 27Cr 24Cr 22Cr 42Cr 2.78TCr 43Cr 291.87Cr 116.33Cr 1.49TCr 111.5Cr 109.11Cr 4.7TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	39Cr 35Cr 32Cr 29Cr 56Cr 3.68TCr 57Cr 386.28Cr 153.96Cr 1.97TCr 147.56Cr 144.4Cr 6.21TCr	EV / Sales 2026 *	-	EV / Sales 2027 *	10.8x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Northwest Biotherapeutics, Inc

31/10	Northwest Biotherapeutics, Inc. Enters into Commercial Loan Agreement with Streeterville Capital, LLC for USD 5,505,000	CI
09/10	Northwest Biotherapeutics, Advent Bioservices And The UK National Health Service Blood And Transplant Announce Collaboration To Support DCVax®-L Production	CI
15/08	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
16/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/25/31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/25/27	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

26/10	Northwest Biotherapeutics Announces Expansion of Its Technical Team: Company Expanding Key Operational Areas	PU
26/10	Northwest Biotherapeutics Announces Expansion of Its Technical Team	PR
09/10	Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production	PR
06/10	Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference	PR
15/08	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+2.24%	+5.83%	+58.47%	+65.65%	6.67TCr
ARGENX SE	+4.66%	+5.77%	+16.93%	+82.87%	5.69TCr
LONZA GROUP AG	-0.60%	+2.36%	+24.32%	+97.19%	5.65TCr
BEONE MEDICINES AG	+2.55%	+15.52%	+26.77%	+120.17%	4.65TCr
IQVIA HOLDINGS INC.	+2.58%	+7.89%	+30.88%	+45.30%	4.48TCr
REVOLUTION MEDICINES, INC.	+4.09%	+6.37%	+219.07%	+899.75%	4.16TCr
CELLTRION, INC.	-0.47%	+9.60%	+27.53%	+52.88%	3.53TCr
GENMAB A/S	+3.80%	-6.42%	+98.16%	+68.09%	3.33TCr
INSMED INCORPORATED	+1.48%	+6.21%	-39.51%	+395.73%	2.51TCr
Average	+2.31%	+3.29%	+51.40%	+203.07%	4.52TCr
Weighted average by Cap.	+2.36%	+3.97%	+52.19%	+181.18%

	2026 *	2027 *
Net sales	-	3.89Cr 3.48Cr 3.2Cr 2.9Cr 5.5Cr 364.94Cr 5.64Cr 38Cr 15Cr 195.38Cr 15Cr 14Cr 615.36Cr
Net income	-	-
Net Debt	9.61Cr 8.58Cr 7.89Cr 7.16Cr 14Cr 900.57Cr 14Cr 94Cr 38Cr 482.14Cr 36Cr 35Cr 1.52TCr	12Cr 11Cr 10Cr 9.31Cr 18Cr 1.17TCr 18Cr 122.76Cr 49Cr 626.95Cr 47Cr 46Cr 1.97TCr

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news: Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile